Insulin-like growth factor 1 (IGF-1) is one of the body’s most versatile signaling molecules, driving everything from childhood bone growth to adult muscle repair and brain cell renewal. Produced mainly by the liver in response to growth hormone, IGF-1 circulates through the bloodstream and acts on tissues throughout the body. That breadth of influence makes it medically valuable in specific deficiency disorders, but it also means that chronically elevated levels are linked to increased cancer risk and cardiovascular problems. The story of IGF-1 is essentially one of balance: too little stunts growth and impairs tissue maintenance, while too much can fuel the very diseases people hope to avoid.
How IGF-1 Is Produced and What Controls It
Growth hormone, released by the pituitary gland, travels to the liver and stimulates it to produce and secrete IGF-1 into the bloodstream.1PubMed. Food deprivation reduces sensitivity of liver Igf1 synthesis pathways to growth hormone in juvenile gopher rockfish (Sebastes carnatus) The liver is the dominant source: when researchers knocked out IGF-1 production specifically in mouse liver cells, circulating IGF-1 levels dropped by about 75%, confirming that the liver accounts for the vast majority of what ends up in the blood.2PubMed Central. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice Other tissues, including muscle and bone, also produce IGF-1 locally, and that local production turns out to matter a great deal. In those same liver-knockout mice, postnatal body growth proceeded normally despite the massive drop in blood IGF-1, suggesting that tissue-level IGF-1 can compensate for what the liver fails to deliver.
Once in the bloodstream, IGF-1 does not float freely. A family of six binding proteins, known collectively as IGF-binding proteins, latch onto IGF-1 and IGF-2 and regulate how much of each reaches the target receptor on cell surfaces.3PubMed. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism Among these, IGFBP-1 is particularly responsive to metabolic shifts and serves as a key regulator of IGF activity in mammals.4PubMed Central. Regulation of IGFBP-1 in Metabolic Diseases Think of the binding proteins as a buffering system: they extend IGF-1’s half-life in the blood, carry it to the right tissues, and prevent it from overwhelming receptors all at once. The signaling that results when IGF-1 does reach its receptor relies primarily on two well-characterized pathways that govern cell growth, survival, and metabolism.5PubMed Central. The signaling landscape of insulin-like growth factor 1
Muscle Growth and Repair
IGF-1’s reputation in fitness and sports circles comes from its documented role in building and maintaining skeletal muscle. The peptide stimulates muscle protein synthesis and, at the same time, suppresses protein breakdown. It also activates satellite cells, the stem-like cells that sit dormant on muscle fibers until damage or mechanical stress triggers them to proliferate and fuse into the fiber, contributing to hypertrophy.6PubMed Central. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy This satellite-cell activation appears to be especially important in aging. Research has shown that IGF-1 can rescue muscle mass lost to aging or prolonged inactivity, largely by reawakening satellite cells that would otherwise remain quiescent.7PubMed. Insulin-like growth factor 1 and muscle growth: implication for satellite cell proliferation
The practical takeaway here is nuanced. Locally produced IGF-1 in muscle tissue, stimulated by exercise, appears to be the main driver of exercise-induced hypertrophy. Circulating IGF-1 from the liver contributes, but the local signal seems to matter more for direct muscle adaptation. This distinction is often lost in marketing materials for IGF-1-related supplements, which tend to focus on blood levels rather than what is happening inside the muscle itself.
Bone Growth
During childhood and adolescence, IGF-1 is indispensable for linear bone growth. Bones lengthen at the growth plate, where cartilage cells called chondrocytes go through stages of proliferation and then enlargement. IGF-1 directly stimulates both of these processes. Studies in mice lacking the IGF-1 gene showed that while their chondrocytes could still differentiate and produce the normal specialized proteins, the cells were physically smaller. The terminal chondrocytes that form the scaffold for long bone extension were reduced in size by about 30%, which accounted for most of the decrease in longitudinal growth.8PubMed. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy
Circulating IGF-1 also influences bone density. Research in mice engineered to have very low blood levels of IGF-1 demonstrated reduced bone length as early as four weeks of age, and the dramatic reduction in circulating IGF-1 was consistent with decreased chondrocyte proliferation at the growth plate.9The Journal of Clinical Investigation. Circulating levels of IGF-1 directly regulate bone growth and density In adults, whose growth plates have closed, IGF-1 continues to support bone remodeling and mineral density, which is one reason why severe IGF-1 deficiency in adulthood is associated with reduced bone mass.
Effects on the Brain and Nervous System
IGF-1 is not just a peripheral growth factor. It crosses the blood-brain barrier and plays an active role in the brain from fetal development through adulthood. During embryonic and early postnatal stages, IGF-1 influences the proliferation of neural stem cells and their differentiation into both neurons and supportive glial cells. It also promotes synapse formation as neurons mature.10PubMed Central. IGF-I: A Key Growth Factor that Regulates Neurogenesis and Synaptogenesis from Embryonic to Adult Stages of the Brain
In the adult brain, IGF-1 is one of the factors that sustains neurogenesis in the hippocampus, a region critical for learning and memory. Because most IGF-1 in the adult body originates outside the brain and its entry into the brain depends partly on physical activity, researchers have proposed that IGF-1 serves as a link between bodily activity and brain plasticity. When you exercise and IGF-1 levels rise, some of that IGF-1 reaches the brain and supports the birth of new neurons and their survival.11PubMed. Mechanisms mediating brain plasticity: IGF1 and adult hippocampal neurogenesis This may help explain part of the well-documented cognitive benefits of regular exercise, though IGF-1 is only one piece of a much larger puzzle.
Metabolic Roles and Glucose Regulation
IGF-1 got its name because it structurally resembles insulin, and some of its functions overlap with insulin’s. IGF-1 can promote glucose uptake into cells and improve insulin sensitivity. In mouse experiments, central administration of IGF-1 improved both glucose tolerance and insulin sensitivity.12Nutrition & Diabetes. Central IGF1 improves glucose tolerance and insulin sensitivity in mice In the context of normal physiology, IGF-1 acts as a supporting player to insulin in maintaining blood sugar within a healthy range.
The flip side of this insulin-like activity is the risk of hypoglycemia, which becomes especially relevant when IGF-1 is administered as a drug. In animal studies, injected IGF-1 caused blood sugar to drop in a dose-dependent fashion, with glucose levels falling by 40 to 52% depending on the group.13PubMed. Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect? This hypoglycemic effect is one of the main practical barriers to using IGF-1 therapeutically at higher doses.
Approved Medical Uses
The only approved clinical use of recombinant IGF-1 is for children with severe primary IGF-1 deficiency, a rare condition in which the body cannot produce enough IGF-1 despite having normal or elevated growth hormone. The drug, called mecasermin, has been available since 1986 but was not approved by the FDA until 2005 and by the European Medicines Agency until 2007.14PubMed Central. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency
Mecasermin works, but expectations need to be realistic. While most treated children do not achieve a final height in the normal range, many reach an adult height meaningfully greater than what they would have been expected to attain without treatment.15PubMed. Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency The therapy requires regular injections, typically twice daily, and must be carefully managed to avoid side effects like hypoglycemia, which is the most common adverse event.
Beyond growth disorders, IGF-1 has been explored experimentally in nerve repair. In one animal study, local application of IGF-1 combined with an artery graft accelerated functional recovery of the sciatic nerve and improved the quality of regenerated axons compared to the graft alone.16PubMed. Effect of local administration of insulin-like growth factor I combined with inside-out artery graft on peripheral nerve regeneration This line of research is still preclinical, but it hints at potential applications in peripheral nerve injuries where standard repair methods yield slow or incomplete recovery.
Cancer Risk
The same cell-growth-promoting properties that make IGF-1 useful for tissue building also make it a concern in cancer biology. Epidemiological studies have repeatedly found that higher circulating IGF-1 levels are associated with increased risk of several common cancers, including breast, prostate, and colorectal cancer.17PubMed. Insulin-like growth factors and cancer A large European cohort study provided more precise estimates, finding that each standard-deviation increase in IGF-1 was associated with roughly a 25% higher risk of breast cancer and a 31% higher risk of prostate cancer.18The Journal of Clinical Endocrinology & Metabolism. IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg
The relationship between IGF-1 and cancer extends to the possibility that elevated levels may promote second primary cancers in people who have already been treated for an initial malignancy.19PubMed Central. Is there a role for IGF‑1 in the development of second primary cancers? The mechanisms likely involve IGF-1’s ability to stimulate cell proliferation and survival while suppressing the natural cell-death pathways that normally keep precancerous cells in check. In colorectal cancer cells specifically, IGF-1 has been shown to activate glucose transporters and glycolytic enzymes that allow tumors to fuel their growth through increased sugar metabolism.20PubMed Central. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
It is worth stressing that these findings are associational. Having higher IGF-1 does not guarantee cancer, and having lower levels does not guarantee protection. But the pattern is consistent enough that researchers and clinicians take it seriously, particularly in the context of exogenous IGF-1 use for performance or anti-aging purposes.
Cardiovascular and Cardiometabolic Concerns
IGF-1 signaling plays roles in the heart that are both protective and potentially harmful, depending on the dose and duration. At physiological levels, IGF-1 supports normal cardiac growth and can protect heart cells from stress-induced death. But chronic overexposure tells a different story. Research into patients with acromegaly, a condition defined by excess growth hormone and, consequently, elevated IGF-1, provides a natural experiment. In treated acromegaly patients, a higher cumulative IGF-1 burden was significantly associated with cerebrovascular disease and cardiomyopathy.21PubMed. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly
A detailed review of IGF-1 signaling in the heart has highlighted that myocardial hypertrophy, cell death, fibrosis, and electrical remodeling are all influenced by IGF-1 and its receptor, and these processes contribute to the progression of heart failure when they proceed unchecked.22Physiology (Bethesda) / American Physiological Society. New Insights into IGF-1 Signaling in the Heart The practical implication is that artificially elevating IGF-1 levels, especially over extended periods, carries real cardiovascular risks that go beyond what most people anticipate when they think of IGF-1 as simply a “muscle-building” peptide.
The Longevity Paradox
If IGF-1 promotes growth, repair, and tissue maintenance, you might assume that more of it would extend life. Animal research suggests the opposite. Rodent models with reduced activity in the growth hormone/IGF-1 signaling pathway consistently live longer than their normal counterparts. Caloric restriction, one of the most robust interventions for extending lifespan in laboratory animals, appears to work partly by dampening this same axis.23PubMed Central. Role of insulin and growth hormone/insulin-like growth factor-I signaling in lifespan extension: rodent longevity models for studying aging and calorie restriction
Interestingly, not all long-lived rodents with reduced IGF-1 signaling show improved insulin sensitivity, which was once assumed to be the unifying mechanism. Some display normal or even reduced insulin sensitivity, suggesting that the lifespan benefits stem more from changes in intracellular signaling downstream of the IGF-1 receptor than from improved sugar handling per se. This finding complicates the popular narrative that “lower IGF-1 equals healthier aging,” since the relationship appears to be less about the raw blood level and more about how cells are responding to the signal internally.
Translating this to humans remains uncertain. Epidemiological data in people tells a more complicated tale than the clean rodent results, with both very low and very high IGF-1 levels linked to increased mortality in some studies. The safest interpretation is that the body likely benefits from keeping IGF-1 within a moderate physiological range rather than pushing it to either extreme.
How Diet and Exercise Shape Your IGF-1 Levels
Your body’s IGF-1 output is not fixed. It responds to what you eat, how much you eat, and how you move. Protein intake is one of the stronger dietary drivers. In a large observational study, adjusted mean IGF-1 levels rose with increasing protein consumption across both younger and older adults.24Cell Metabolism. Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population That study also found that high protein intake was associated with higher cancer and overall mortality in people aged 65 and younger, and that IGF-1 moderated this association. In adults over 65, however, higher protein and higher IGF-1 were not associated with the same mortality increase, pointing to different risk-benefit profiles depending on age.
Exercise produces a transient spike in free IGF-1 immediately after a workout, and dietary protein on its own can raise 24-hour IGF-1 levels by about 17% above baseline.25PubMed Central. Exercise, Dietary Protein, and Combined Effect on IGF-1 Combining exercise and protein, somewhat surprisingly, did not amplify the IGF-1 response beyond what each intervention produced alone in that particular study. Fasting, by contrast, appears to lower IGF-1. A systematic review and meta-analysis of randomized controlled trials found that fasting regimens substantially reduced circulating IGF-1, while ordinary caloric restriction had a weaker and less consistent effect unless the energy deficit exceeded 50% of normal daily intake.26PubMed. The influence of fasting and energy restricting diets on IGF-1 levels in humans: A systematic review and meta-analysis
These findings suggest that people who want to manage their IGF-1 levels have practical levers available. Moderating protein intake and incorporating periodic fasting can lower circulating levels, while resistance exercise and higher protein consumption can raise them. Which direction you want to push likely depends on your age, health status, and whether you are dealing with muscle wasting, cancer risk, or neither.
Off-Label Use and Anti-Doping Detection
Outside the narrow approved indication for growth failure, IGF-1 has attracted interest from athletes and bodybuilders seeking a competitive edge or faster recovery. The peptide is banned by the World Anti-Doping Agency, and detection methods are evolving. Current anti-doping testing for growth hormone abuse relies in part on measuring IGF-1 and another biomarker called P-III-NP in athlete blood profiles. Data from over 11,000 elite athletes have been used to build population-level reference ranges, against which an individual athlete’s values are compared over time using a biological passport approach.27PubMed. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping
A newer frontier in doping detection involves gene doping, where an athlete might inject a viral vector carrying the IGF-1 gene directly into muscle tissue to boost local production without obviously spiking blood levels. Researchers have developed sensitive digital PCR methods that can detect IGF-1 transgenic elements in blood for at least 33 days after a single intramuscular injection in mice.28PubMed Central. Transgene detection by digital droplet PCR Whether this technology can scale to routine human testing remains to be seen, but its development signals that anti-doping authorities are anticipating the next generation of performance-enhancing strategies.
For people who are not competitive athletes, the more immediate concern with off-label IGF-1 use is safety. The peptides sold through gray-market suppliers often come without reliable purity testing, and self-administering a hormone that promotes cell proliferation, lowers blood sugar, and affects the heart carries meaningful risks. The hypoglycemia alone can be dangerous, particularly in people who are also dieting or using insulin. Stacking IGF-1 with other peptides or hormones, as many online protocols recommend, only multiplies the unknowns.